Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cocktail targets Hard-to-Treat lymphoma

NCT ID NCT05626322

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a combination of three drugs—maplirpacept, tafasitamab, and lenalidomide—in 6 people with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy. The goal was to find a safe and effective dose of maplirpacept when added to the other two drugs. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
maplirpacept (PF-07901801), tafasitamab, and lenalidomide
What this could lead to
If this combination works, it could offer a new treatment option for people with DLBCL who cannot have a stem cell transplant or CAR-T therapy.
What could go wrong
This is a very early, small trial (only 6 participants) that was terminated, so results are limited. The combination may cause serious side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

6 people

The number who actually took part.

Started

Aug 2023

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Histologically confirmed diagnosis of DLBCL * Relapsed or refractory disease * Participant is not be a candidate for or is unwilling to undergo high dose chemotherapy and subsequent stem cell transplant and/or is unable to receive chimeric antigen receptor (CAR) T-cell therapy * Previous treatment with at least one prior line of systemic therapy (for phase 2, at least 1 and no more than 2 prior lines of systemic therapy). Prior therapy must include an anti-CD20 antibody. * Adequate bone marrow, hepatic and renal function * Eastern Cooperative Oncology Group (ECOG) ≤2 * Must provide a tumor tissue sample (fresh or archival, collected prior to start of treatment) for biomarker analysis Key Exclusion Criteria: * Prior treatment with an anti-CD47 or anti-CD19 (other than CAR T) or immunomodulatory agents * Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment * Participants with active, uncontrolled bacterial, fungal or viral infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma

Contacts and locations

Locations

  • Dong-A University Hospital

    Busan, Pusan-kwangyǒkshi, 49201, South Korea

  • Lifespan Cancer Institute

    Providence, Rhode Island, 02903, United States

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana, 70809, United States

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea

  • The Miriam Hospital

    Providence, Rhode Island, 02906, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Yamagata University Hospital

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.